Epidemiology and economic burden of meningococcal disease in Germany: A systematic review.


Journal

Vaccine
ISSN: 1873-2518
Titre abrégé: Vaccine
Pays: Netherlands
ID NLM: 8406899

Informations de publication

Date de publication:
18 03 2022
Historique:
received: 24 08 2021
revised: 03 12 2021
accepted: 09 02 2022
pubmed: 2 3 2022
medline: 19 4 2022
entrez: 1 3 2022
Statut: ppublish

Résumé

Invasive meningococcal disease (IMD) is a notifiable disease in Germany and other European countries. Due to the high lethality of the disease and the risk of long-term consequences, IMD prevention is of high public health relevance despite the low number of cases in the population. This study aims to describe key epidemiological and economic parameters of IMD in Germany to support national decision-making processes for implementing enhanced prevention measures. Based on a systematic literature review in PubMed and EMBASE, all publications on the burden of disease and costs of IMD published up to May 2020 were evaluated. Additionally, notification data were used to report the annual case numbers and incidence of IMD in Germany until the end of 2019. Thirty-six studies were included, of which 35 reported data on the epidemiological burden of disease and three reported data on economic aspects of IMD. The type of reported endpoints and results on the incidence of IMD differed widely by reporting year, population, and data source used. Most of the data are reported without specific information about a serogroup. Data on the economic burden of disease and healthcare resource use are scarce. Based on mandatory notification data, a decrease in the incidence of notified IMD cases has been observed since 2004. Currently, the nationwide annual incidence in Germany is at 0.3 cases per 100,000 persons and has gradually decreased. While the overall decline is mainly attributable to MenB, cases with MenY and MenW are the only ones that have increased on a low level in recent years. While IMD is a rare disease, high direct and indirect costs illustrate the relevance of the disease for patients, caregivers, as well as for the health care system. Future research should concentrate on quantifying the long-term economic burden and indirect costs of meningococcal disease. Integrated IMD surveillance with isolate characterisation remains crucial to inform public health policies.

Identifiants

pubmed: 35227520
pii: S0264-410X(22)00189-X
doi: 10.1016/j.vaccine.2022.02.043
pii:
doi:

Substances chimiques

Meningococcal Vaccines 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't Review Systematic Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

1932-1947

Informations de copyright

Copyright © 2022 The Authors. Published by Elsevier Ltd.. All rights reserved.

Auteurs

S Gruhn (S)

Department for Health Economics and Health Care Management, School of Public Health, Bielefeld University, Germany. Electronic address: s.gruhn@uni-bielefeld.de.

J Witte (J)

Department for Health Economics and Health Care Management, School of Public Health, Bielefeld University, Germany; Vandage GmbH, Bielefeld, Germany. Electronic address: julian.witte@vandage.de.

W Greiner (W)

Department for Health Economics and Health Care Management, School of Public Health, Bielefeld University, Germany. Electronic address: wolfgang.greiner@uni-bielefeld.de.

O Damm (O)

Sanofi-Aventis Deutschland GmbH, Germany. Electronic address: oliver.damm@sanofi.com.

M Dietzsch (M)

Sanofi-Aventis Deutschland GmbH, Germany. Electronic address: marie.dietzsch@sanofi.com.

R Kramer (R)

Sanofi-Aventis Deutschland GmbH, Germany. Electronic address: rolf.kramer@sanofi.com.

M Knuf (M)

Klinik für Kinder- und Jugendmedizin, Helios Dr. Horst Schmidt Kliniken, Wiesbaden, Germany; Klinik für Kinder- und Jugendmedizin, Klinikum Worms gGmbH, Worms, Germany; Pädiatrische Infektiologie, Universitätsmedizin Mainz, Germany. Electronic address: markus.knuf@klinikum-worms.de.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH